ArticleCancers2024

A Novel Triplet of Alisertib Plus Ibrutinib Plus Rituximab Is Active in Mantle Cell Lymphoma.

Baskaran Subramani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.